Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The American College of Cardiology (ACC) has recommended Boehringer Ingelheim’s Pradaxa, the first drug to be cleared in the US as an alternative to the blood thinner Warfarin, for patients with an irregular heartbeat.
Subscribe to our email newsletter
Pradaxa (dabigatran etexilate) is Boehringer Ingelheim’s novel, oral direct thrombin inhibitor for stroke risk reduction in patients with non-valvular atrial fibrillation (AF).
According to a statement, the Washington-based cardiologists’ group, the Dallas-based American Heart Association and the Washington-based Heart Rhythm Society have issued the updated treatment guidelines.
University of Wisconsin-Madison professor of medicine and physiology, and head of the writing subcommittee for the drug Craig January said that doctors have started garnering experience with Pradaxa, and some may opt to wait before prescribing the medicine widely given that it has an impressive roll-out for a new drug.
In a note to investors, JP Morgan Chase analyst Chris Schott has opined that the demand for Boehringer’s new pill indicates room in the market for experimental rivals such as Bristol-Myers Squibb and Pfizer’s apixaban; Merck and Portola Pharmaceuticals’ betrixaban.